NORDIC NANOVECTOR
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medi... cal need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.
NORDIC NANOVECTOR
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2009-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.nordicnanovector.com
Total Employee:
11+
Status:
Active
Contact:
+47 22 18 33 01
Email Addresses:
[email protected]
Total Funding:
29.89 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS
Similar Organizations
Oxitec
Oxitec develops an environment-friendly technology for the control of significant insect pests to prevent diseases and agricultural damage.
Current Employees Featured
Founder
Stock Details
Investors List
Norwegian Research Council
Norwegian Research Council investment in Grant - Nordic Nanovector
Birk Venture
Birk Venture investment in Seed Round - Nordic Nanovector
Key Employee Changes
Official Site Inspections
http://www.nordicnanovector.com Semrush global rank: 6.61 M Semrush visits lastest month: 927
- Host name: 104.18.22.77
- IP address: 104.18.22.77
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Nordic Nanovector"
Nordic Nanovector - Crunchbase Company Profile
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers. View contacts for Nordic Nanovector to access new leads and connect with decision-makers.See details»
Thor Medical | Alpha emitters for cancer therapy
Thor Medical is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium (Th-232).See details»
Nordic Nanovector announces agreement to acquire …
Nordic Nanovector ASA (OSE: NANOV) and Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, today announce that they have entered into a definitive share …See details»
Nordic Nanovector announces agreement to acquire Thor …
Jun 6, 2023 · Thor Medical, based in Oslo, Norway, is a private company that has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters …See details»
Nordic Nanovector ASA - Company Profile & Staff Directory
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of …See details»
Nordic Nanovector - Craft
Jan 28, 2021 · Nordic Nanovector has 5 employees across 3 locations and kr4.11 m in annual revenue in FY 2023. See insights on Nordic Nanovector including office locations, competitors, …See details»
Nordic Nanovector announces agreement to acquire Thor …
Jun 6, 2023 · er shareholders of Thor Medical will own 50% of the post-transaction combined entity and existing Nordic Nanovector shareholders will own 50%. Scatec Innovation AS, …See details»
Nordic Nanovector Company Information - Funding, Investors, …
Get information on funding, investors, industries, and more for Nordic Nanovector. See Nordic Nanovector company profile and funding data.See details»
Nordic Nanovector ASA publishes 2020 Annual Report
Mar 26, 2021 · Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company …See details»
Nordic Nanovector ASA Results for the Second Half and Full Year …
OSLO, Norway, Feb. 28, 2023 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces its results for the second half and full year 2022. A...See details»
Q2 and First Half 2022 Results - Nordicnanovector
IR contact: [email protected] Q2 and First Half 2022 Results. JAN H. EGBERTS, M.D., CHAIR. MALENE BRONDBERG, INTERIM CEO & CFO. Forward-looking statements. This …See details»
Nordic Nanovector ASA: Results for the Third Quarter 2021 - PR …
Nov 18, 2021 · Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company …See details»
Nordic Nanovector Announces Changes to its Executive
May 4, 2020 · As a result of the cost-saving initiatives announced on 2 April 2020, the Board of Directors of Nordic Nanovector has restructured the senior management team. The …See details»
Nordic Nanovector ASA publishes Annual Report 2021
Apr 6, 2022 · Email: [email protected] About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address …See details»
H1 and Q2’2021 HIGHLIGHTS AND FINANCIALS
These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on …See details»
Nordic Nanovector Highlights Novel Humanized Anti-CD37 …
OSLO, Norway, Nov. 3, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces the progress it has made in designing and …See details»
Nordic Nanovector provides Phase II trial update - NLS
Feb 18, 2021 · Nordic Nanovector provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin in 3rd-line relapsed/refractory follicular lymphoma. Despite COVID has the …See details»
Nordic Nanovector R&D Day: Building Value from Betalutin® and …
Nov 30, 2021 · Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in …See details»
Nordic Nanovector OB:NANOV Stock Report - Simply Wall St
Jul 4, 2023 · www.nordicnanovector.com Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company’s lead product …See details»
Nordic Nanovector to present at 3rd Targeted …
Dec 7, 2021 · Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in …See details»